Showing results (51-60 of 124) with videos related to
Sort By:
Pageof 13
Circulation|October 9, 2014
Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialLars Wallentin, Ziad Hijazi, Ulrika Andersson, et al.Heart (British Cardiac Society)|November 1, 2016
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillationM Cecilia Bahit, Renato D Lopes, Daniel M Wojdyla, et al.JAMA Cardiology|July 21, 2016
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical TrialZiad Hijazi, Stefan H Hohnloser, Ulrika Andersson, et al.American Heart Journal|December 16, 2014
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialChristopher B Granger, Renato D Lopes, Michael Hanna, et al.Journal of the American Heart Association|January 19, 2017
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE TrialPeter T Hu, Renato D Lopes, Susanna R Stevens, et al.European Heart Journal|April 19, 2013
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trialSana M Al-Khatib, Laine Thomas, Lars Wallentin, et al.Heart (British Cardiac Society)|January 21, 2018
Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve diseaseDragos Vinereanu, Alice Wang, Hillary Mulder, et al.American Heart Journal|May 15, 2022
Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state modelJulia Aulin, Ziad Hijazi, Johan Lindbäck, et al.Journal of the American College of Cardiology|March 25, 2014
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical OutcomesElaine M Hylek, Claes Held, John H Alexander, et al.Heart (British Cardiac Society)|September 17, 2020
Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillationAnthony P Carnicelli, Sana M Al-Khatib, Denis Xavier, et al.Pageof 13